de STRS Ohio Teva Pharmaceutical Industries Limited TEVA Historial de posiciones en acciones
Compró
Mantenido
Vendió
| Trimestre | Valor de mercado | Estado | Núm. de acciones |
Cambio en la participación | Valor operado | Peso en el portafolio | Posición de la cartera | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | – | Vender |
-291,072
| Cerradas | -USD 9.9 M | – | 2336 |
|
|
2026
Q2 | USD 9.9 M | Vender |
291,072
-246,778
| -46% | -USD 8.22 M | 0.04% | 382 |
|
|
2026
Q1 | USD 16.2 M | Vender |
537,850
-28,711
| -5% | -USD 924 k | 0.06% | 305 |
|
|
2025
Q4 | USD 17.7 M | Vender |
566,561
-196,346
| -26% | -USD 4.84 M | 0.07% | 296 |
|
|
2025
Q3 | USD 15.4 M | Vender |
762,907
-26,238
| -3% | -USD 461 k | 0.06% | 327 |
|
|
2025
Q2 | USD 13.2 M | Comprar |
789,145
+636,015
| +415% | +USD 10.3 M | 0.05% | 349 |
|
|
2025
Q1 | USD 2.35 M | Vender |
153,130
-472,000
| -76% | -USD 8.43 M | 0.01% | 563 |
|
|
2024
Q4 | USD 13.8 M | Vender |
625,130
-584
| -0.1% | -USD 10.6 k | 0.05% | 328 |
|
|
2024
Q3 | USD 11.3 M | Vender |
625,714
-100,000
| -14% | -USD 1.75 M | 0.04% | 362 |
|
|
2024
Q2 | USD 11.8 M | Vender |
725,714
-64,880
| -8% | -USD 999 k | 0.05% | 348 |
|
|
2024
Q1 | USD 11.2 M | Comprar |
790,594
+171,700
| +28% | +USD 2.16 M | 0.04% | 352 |
|
|
2023
Q4 | USD 6.46 M | Comprar |
618,894
+956
| +0.2% | +USD 8.93 k | 0.03% | 423 |
|
|
2023
Q3 | USD 6.3 M | Comprar |
617,938
+282,300
| +84% | +USD 2.63 M | 0.03% | 416 |
|
|
2023
Q2 | USD 2.53 M | Comprar |
335,638
+142
| +0% | +USD 1.15 k | 0.01% | 550 |
|
|
2023
Q1 | USD 2.97 M | Vender |
335,496
-851,810
| -72% | -USD 8.42 M | 0.01% | 524 |
|
|
2022
Q4 | USD 10.8 M | Comprar |
1,187,306
+561,595
| +90% | +USD 4.9 M | 0.05% | 373 |
|
|
2022
Q3 | USD 5.05 M | Comprar |
625,711
+133,811
| +27% | +USD 1.18 M | 0.02% | 455 |
|
|
2022
Q2 | USD 3.7 M | Mantener |
491,900
| – | – | 0.02% | 507 |
|
|
2022
Q1 | USD 4.62 M | Mantener |
491,900
| – | – | 0.02% | 509 |
|
|
2021
Q4 | USD 3.94 M | Comprar |
491,900
+410,900
| +507% | +USD 3.71 M | 0.01% | 537 |
|
|
2021
Q3 | USD 788 k | Mantener |
81,000
| – | – | ﹤0.01% | 1268 |
|
|
2021
Q2 | USD 801 k | Vender |
81,000
-1,200
| -1% | -USD 12.7 k | ﹤0.01% | 1334 |
|
|
2021
Q1 | USD 948 k | Vender |
82,200
-90,900
| -53% | -USD 1.04 M | ﹤0.01% | 1201 |
|
|
2020
Q4 | USD 1.67 M | Mantener |
173,100
| – | – | 0.01% | 780 |
|
|
2020
Q3 | USD 1.56 M | Vender |
173,100
-633,946
| -79% | -USD 6.71 M | 0.01% | 720 |
|
|
2020
Q2 | USD 10 M | Vender |
807,046
-97,000
| -11% | -USD 1.1 M | 0.04% | 343 |
|
|
2020
Q1 | USD 8.12 M | Vender |
904,046
-573,854
| -39% | -USD 5.88 M | 0.04% | 349 |
|
|
2019
Q4 | USD 14.5 M | Mantener |
1,477,900
| – | – | 0.06% | 322 |
|
|
2019
Q3 | USD 10.2 M | Vender |
1,477,900
-173,800
| -11% | -USD 1.33 M | 0.04% | 361 |
|
|
2019
Q2 | USD 15.2 M | Comprar |
1,651,700
+1,569,500
| +1,909% | +USD 18.9 M | 0.07% | 307 |
|
|
2019
Q1 | USD 1.29 M | Vender |
82,200
-1,036,943
| -93% | -USD 18.3 M | 0.01% | 738 |
|
|
2018
Q4 | USD 17.3 M | Vender |
1,119,143
-140,800
| -11% | -USD 2.89 M | 0.09% | 273 |
|
|
2018
Q3 | USD 27.1 M | Comprar |
1,259,943
+402,800
| +47% | +USD 9.35 M | 0.12% | 222 |
|
|
2018
Q2 | USD 20.8 M | Comprar |
857,143
+372,150
| +77% | +USD 7.59 M | 0.09% | 272 |
|
|
2018
Q1 | USD 8.29 M | Comprar |
484,993
+159,300
| +49% | +USD 3.11 M | 0.04% | 381 |
|
|
2017
Q4 | USD 6.17 M | Comprar |
325,693
+269,700
| +482% | +USD 4.06 M | 0.03% | 437 |
|
|
2017
Q3 | USD 985 k | Mantener |
55,993
| – | – | ﹤0.01% | 866 |
|
|
2017
Q2 | USD 1.86 M | Mantener |
55,993
| – | – | 0.01% | 636 |
|
|
2017
Q1 | USD 1.8 M | Mantener |
55,993
| – | – | 0.01% | 656 |
|
|
2016
Q4 | USD 2.03 M | Vender |
55,993
-50,000
| -47% | -USD 2 M | 0.01% | 632 |
|
|
2016
Q3 | USD 4.88 M | Vender |
105,993
-524,600
| -83% | -USD 27.4 M | 0.02% | 500 |
|
|
2016
Q2 | USD 31.7 M | Comprar |
630,593
+21,091
| +3% | +USD 1.12 M | 0.14% | 195 |
|
|
2016
Q1 | USD 32.6 M | Mantener |
609,502
| – | – | 0.15% | 192 |
|
|
2015
Q4 | USD 40 M | Mantener |
609,502
| – | – | 0.18% | 155 |
|
|
2015
Q3 | USD 34.4 M | Vender |
609,502
-377,000
| -38% | -USD 24.4 M | 0.16% | 173 |
|
|
2015
Q2 | USD 58.3 M | Vender |
986,502
-128,000
| -11% | -USD 7.9 M | 0.26% | 107 |
|
|
2015
Q1 | USD 69.4 M | Comprar |
1,114,502
+236,652
| +27% | +USD 13.8 M | 0.31% | 84 |
|
|
2014
Q4 | USD 50.5 M | Mantener |
877,850
| – | – | 0.22% | 133 |
|
|
2014
Q3 | USD 47.2 M | Mantener |
877,850
| – | – | 0.21% | 132 |
|
|
2014
Q2 | USD 46 M | Vender |
877,850
-225,000
| -20% | -USD 11.5 M | 0.21% | 136 |
|
|
2014
Q1 | USD 58.3 M | Vender |
1,102,850
-29,896
| -3% | -USD 1.38 M | 0.26% | 116 |
|
|
2013
Q4 | USD 45.4 M | Vender |
1,132,746
-121,490
| -10% | -USD 4.78 M | 0.2% | 145 |
|
|
2013
Q3 | USD 47.4 M | Comprar |
1,254,236
+25,000
| +2% | +USD 975 k | 0.21% | 143 |
|
|
2013
Q2 | USD 48.2 M | Comprar |
+1,229,236
| Nuevas | +USD 47.9 M | 0.21% | 139 |
|
Otros fondos que tienen TEVA en su cartera
Posición de STRS Ohio en TEVA: resumen de T3 2026
STRS Ohio cerró por completo su posición en Teva Pharmaceutical Industries Limited (TEVA) en T3 2026, liquidando una posición de 291,072 acciones por un valor estimado de USD 9.9 M.
STRS Ohio reportó por primera vez una posición en TEVA en T2 2013 y la mantuvo durante 53 trimestres. La posición alcanzó su máximo de USD 69.4 M en T1 2015. Al cierre de T3 2026, 195 fondos que sigue Wall St. Rank mantienen una posición en TEVA.
- STRS Ohio reportó que ya no tenía una posición en Teva Pharmaceutical Industries Limited al cierre de T3 2026, después de venderla por completo durante el trimestre.
- STRS Ohio vendió 291,072 acciones de Teva Pharmaceutical Industries Limited en T3 2026, por un valor estimado de USD 9.9 M.
- STRS Ohio reportó por primera vez una posición en Teva Pharmaceutical Industries Limited en T2 2013 y la mantuvo durante 53 trimestres.
- La posición de STRS Ohio en Teva Pharmaceutical Industries Limited alcanzó su máximo de USD 69.4 M en T1 2015.
- Al cierre de T3 2026, 195 fondos que sigue Wall St. Rank tenían Teva Pharmaceutical Industries Limited en cartera.
Según el Informe 13F de STRS Ohio correspondiente a T3 2026, presentado el 30 oct 2026.